Pharmaceutical composition for treating liver diseases

Abstract

The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.

What is claimed is: 
     
         1 . A pharmaceutical composition for treating liver diseases, comprising a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein said microRNA mimic is chemically modified for not being degraded by RNase. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein said microRNA mimic is delivered into target cells by transfection and/or conjugate delivery. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein said microRNA mimic is delivered into target cells by conjugate delivery and transfection. 
     
     
         5 . The pharmaceutical composition according to  claim 3  or  4 , wherein said conjugate delivery delivers said microRNA mimic into target cells by binding an aptamer or cholesterol with the microRNA mimic. 
     
     
         6 . The pharmaceutical composition according to  claim 3  or  4 , wherein the transfection delivers said microRNA mimic into target cells by using liposome, exosome, nanoparticle or virus. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein said nanoparticle comprises lipid nanoparticle or polymer nanoparticle. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , which is administered by injection. 
     
     
         9 . The pharmaceutical composition according to  claim 1 , wherein said liver diseases comprise liver cancers and fatty liver diseases. 
     
     
         10 . The pharmaceutical composition according to  claim 9 , which treats liver cancers though decreasing the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B). 
     
     
         11 . The pharmaceutical composition according to  claim 9 , which treats fatty liver diseases though decreasing the expression of acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB) and diglyceride acyltransferase 2 (DGAT2). 
     
     
         12 . A use of a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35) for preparing a drug for liver cancers. 
     
     
         13 . A use of a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35) for preparing a drug for fatty liver diseases. 
     
     
         14 . A method for decreasing the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B) by administering berberine or a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). 
     
     
         15 . A method for decreasing the expression of acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB) and diglyceride acyltransferase 2 (DGAT2) by administering berberine or a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35).